从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.61倍，行业中值37.15倍，理邦仪器排 名第75位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13理邦仪器36.9342.983.3669.68亿行业平均 50.6148.904.58106.48亿行业中值37.1537.712.4550.05亿1英科医疗9.6910.440.86153.03亿2九安医疗 10.2410.350.81172.78亿3新华医疗14.3313.281.1791.85亿4奥美医疗15.0714.771.5554.46亿5振德医疗 15.4914.600.9956.25亿6山东药玻15.5315.581.79146.92亿7康德莱15.6115.621.2933.63亿8维力医疗 16.3316.981.9237.25亿9奥泰生物16.7117.611.3553.28亿10九强生物16.8115.632.0683.25亿11安杰思 17.6817.892.1452.50亿12三鑫医疗18.4818.493.0442.05亿 来源：金融界 截至2025年一季报，共有2家机构持仓理邦仪器，其中其他2家，合计持股数 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of the company, Libang Instruments, within the medical device industry, noting its stock price increase and market capitalization [1] - As of June 23, the stock price of Libang Instruments closed at 11.53 yuan, reflecting a 3.87% increase, with a rolling PE ratio of 35.42 times and a total market value of 6.684 billion yuan [1] - The average PE ratio for the medical device industry is 48.89 times, with a median of 35.79 times, positioning Libang Instruments at the 75th rank within the industry [1][2] Group 2 - The company reported a revenue of 420 million yuan for Q1 2025, showing a year-on-year decrease of 5.25%, while net profit reached 65.0882 million yuan, marking a significant increase of 68.98% [1] - The gross profit margin for the company stands at 58.34%, indicating a strong profitability despite the decline in revenue [1] - The main business of Libang Instruments includes the research, production, sales, and service of medical electronic devices and in vitro diagnostic products, with a diverse range of offerings [1]

5月20日，理邦仪器今日收盘11.92元，上涨1.19%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到36.62倍，总市值69.10亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 截至2025年一季报，共有2家机构持仓理邦仪器，其中其他2家，合计持股数4877.75万股，持股市值5.91 亿元。 深圳市理邦精密仪器股份有限公司的主营业务是从事医疗电子设备产品和体外诊断产品的研发、生产、 销售、服务。公司的主要产品是急危重症监护方案、床旁监护方案、智能生命体征查房方案、静态心 电、运动心电、动态心电/血压、心电网络解决方案、推车式全数字彩色超声诊断系统、便携式全数字 彩色超声诊断系统、全数字超声诊断系统、手持式超声诊断系统、围产监护方案、妇科诊疗方案、盆底 康复方案、血气分析仪、采血器、软件管理产品、磁敏荧光免疫分析仪、血细胞分析仪、分子诊断产 品、智慧健康业务。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，理邦仪器排 名第76位。 来 ...

股东方面，截至2025年4月10日，理邦仪器股东户数28143户，较上次减少288户，户均持股市值35.28万 元，户均持股数量2.76万股。 5月9日，理邦仪器今日收盘11.77元，下跌1.09%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到36.16倍，总市值68.23亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.98倍，行业中值36.16倍，理邦仪器排 名第75位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)75理邦仪器36.1642.093.2968.23亿行业平均 48.9847.404.56104.17亿行业中值36.1637.662.3446.18亿1天益医疗-1712.92-2934.031.8321.83亿2澳华内 镜-592.52297.184.7562.44亿3诺唯赞-411.67-486.902.2688.10亿4爱朋医疗-344.10261.424.1528.23亿5博晖 创新-324.60515.093.4647.63亿6硕世生物-125.58-1835.121.1336.73亿7奥精医疗-121.29-177.781.6022.5 ...

最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)75理邦仪器36.4142.373.3168.69亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿 8睿昂基因-98.61-80.961.4012.76亿9康泰医学-84.98-71.803.0355.93亿10中红医疗-67.51-53.850.8546.92亿 11华大智造-63.30-56.174.36337.46亿 5月6日，理邦仪器今日收盘 ...

最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)75理邦仪器35.8841.763.2767.70亿行业平均 48.1145.994.51102.53亿行业中值35.8836.472.2646.14亿1天益医疗-1660.65-2844.501.7721.16亿2澳华内 镜-568.12284.944.5559.87亿3诺唯赞-410.18-485.142.2587.78亿4博晖创新-322.37511.563.4447.30亿5爱朋 医疗-299.71227.693.6124.59亿6硕世生物-125.29-1830.871.1236.65亿7奥精医疗-116.13-170.211.5321.55亿 8睿昂基因-94.34-77.451.3412.21亿9康泰医学-83.02-70.152.9654.65亿10中红医疗-66.39-52.950.8446.14亿 11华大智造-62.30-55.294.29332.17亿 来源：金融界 4月30日， ...